Clinically, HER2 and EGFR overexpression and the associated increase in cellular signal transduction is a common feature of tumours such as breast cancer and gastric cancer, and is associated with aggressive disease (Yonemura et al, 1991; Salomon et al, 1995; Nicolini et al, 2006). Here, ERBB2 is linked to neoplasm.